Additional file 2: Table S2. of Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Two hundred sixty-seven proteins identified by LC-MS/MS analysis. (XLSX 106 kb

Additional file 1: Figure S1. of Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Screening of marker candidates in serum samples from patients with AAV. Figure S2. Schematic diagram of targeted proteomics using the LC-SRM assay. Figure S3. Correlations between the light/heavy ratio of SRM and the ELISA titers of markers. Figure S4 Correlation of marker levels with total BVAS score of patients with AAV. Table S1. Clinical data on healthy donors and patients with RA, SLE, and infectious diseases. Table S3. Selected marker candidates for SRM assay development. Table S4. A set of established SRM transitions for the detection of marker candidates. Table S5. The 20 proteins with a significant change before and at 6 months after treatment in protocol 1 (n = 23) and protocol 2 (n = 29) in the SRM assay. Table S6. Comparison of serum levels of biomarker candidates between the remission group (n = 62) and the nonremission group (n = 17) at 6 months after treatment. Table S7. Marker levels in old healthy donors. Table S8. Comparison of serum levels of biomarker candidates between the patients with AAV with (n = 120) and without (n = 49) renal involvement before treatment. Table S9. Comparison of serum levels of biomarker candidates between the patients with AAV with and without lung involvement before treatment. Table S10. Comparison of marker levels among MPA, GPA, and EGPA before treatment. Table S11 Association of marker levels with disease severity in patients with AAV before treatment. (PDF 2221 kb